Clinical trial NCT01242917: A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Rheumatoid Arthritis
Lead sponsor: Amgen
Sponsor class: INDUSTRY
First posted: 2010-11-17
Enrollment: 159
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the safety and efficacy of CCX354-C in subjects with rheumatoid arthritis partially responsive to methotrexate therapy.

Detailed description: Study acquired by Amgen and all disclosures were done by previous sponsor ChemoCentryx.

Eligibility criteria: Inclusion Criteria:

1. Male or female subjects, aged 18-75 years inclusive, with functional class I to III rheumatoid arthritis (RA) based on American College of Rheumatology (ACR) criteria for at least 3 months prior to screening; wheel-chair bound subjects or those with irreversible disease will not be eligible;
2. Subjects must have active RA, defined by a minimum of 8 swollen joints and 8 tender/painful joints (based on 66/68 joint count), at screening
3. Serum C-reactive protein (CRP) above 5 mg/L at screening;
4. Must have been on methotrexate (7.5 to 25 mg/week) taken orally, subcutaneously, or intramuscularly for ≥ 16 weeks and on a stable dose for ≥ 8 weeks prior to randomization;
5. If on hydroxychloroquine, must have been on a stable dose for ≥ 16 weeks prior to randomization;
6. If taking non-steroidal anti-inflammatory drugs (NSAIDs), must have been on stable doses for ≥ 2 weeks before randomization;
7. If taking oral corticosteroids, subjects may not take more than 10 mg/day of prednisone or equivalent, and must have been on a stable dose for ≥ 4 weeks before randomization;
8. Willing and able to give written Informed Consent and to comply with the requirements of the study protocol;
9. Negative result of the human immunodeficiency virus (HIV) screen, the hepatitis B screen, and the hepatitis C screen;
10. Judged to be otherwise healthy by the Investigator, based on medical history, physical examination (including electrocardiogram \[ECG\]), and clinical laboratory assessments;
11. Female subjects of childbearing potential, and male subjects with partners of childbearing potential, may participate if adequate contraception is used during, and for at least the four weeks after administration of study medication

Exclusion Criteria:

1. Diagnosed with RA prior to 16 years of age;
2. Women who are pregnant, breastfeeding, or have a positive serum pregnancy test at screening;
3. History within one year prior to randomization of illicit drug use;
4. History of alcohol abuse at any time in the past;
5. Have received sulfasalazine, azathioprine, 6-mercaptopurine, mycophenolate mofetil, tetracycline, cyclosporine, gold, tacrolimus, sirolimus, or other disease modifying anti-rheumatic drug (DMARD) within 8 weeks of randomization;
6. Use of infliximab, adalimumab, abatacept, certolizumab, golimumab, or tocilizumab within 8 weeks of randomization;
7. Use of leflunomide within 6 months of randomization;
8. Use of etanercept or anakinra within 4 weeks of randomization;
9. Use of a B-cell depleting agent such as rituximab or ocrelizumab, or cytotoxic agents, such as cyclophosphamide or chlorambucil, within one year of randomization;
10. Currently taking cytochrome P450 inhibitors including protease inhibitors such as ritonavir, indinavir, nelfinavir, or macrolide antibiotics such as erythromycin, telithromycin, clarithromycin, or azole antifungals such as fluconazole, ketoconazole, itraconazole, or cimetidine, nefazodone, bergamottin (constituent of grapefruit juice), quercetin, aprepitant, or verapamil;
11. Currently taking cytochrome P450 inducers including St. John's wort, rifampicin, rifabutin, rifapentin, dexamethasone, phenytoin, carbamazapine, phenobarbitol, or troglitazone;
12. Intra-articular, intravenous, or intramuscular corticosteroid injection within 4 weeks of randomization;
13. History or presence of any form of cancer within the 10 years prior to randomization, with the exception of excised basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis;
14. Evidence of tuberculosis (TB) based on chest X rays, tuberculin skin test, QuantiFERON®-TB Gold test, or T-SPOT®.
15. Presence of Felty's syndrome, psoriatic arthritis, gout, or other auto-immune diseases;
16. Major surgery (including joint surgery) within 12 weeks prior to randomization;
17. The subject had an infection requiring antibiotic treatment within 4 weeks of randomization;
18. Subject has any evidence of hepatic disease; Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), alkaline phosphatase, or bilirubin \> 1.5 x the upper limit of normal;
19. Subject has any evidence of renal impairment; serum creatinine \> 1.5 x upper limit of normal or estimated Glomerular Filtration Rate (GFR) based on the Cockcroft-Gault equation \< 30 mL/min;
20. History or presence of any medical or psychiatric condition or disease, or laboratory abnormality that, in the opinion of the Investigator, may place the subject at unacceptable risk for study participation and may prevent the subject from completing the study
21. Participated in any clinical study of an investigational product including CCX354-C within 30 days or 5 times the half life of the agent, whichever is longer, prior to randomization

Primary outcomes:
measure: Subject incidence of adverse events
timeFrame: 12 weeks
Secondary outcomes:
measure: The change from baseline to week 12 of Disease Activity Score for 28 Joints using C-reactive proteine (DAS28-CRP)
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Brussels
country: Belgium
city: Kortrijik
country: Belgium
city: Liege
country: Belgium
city: Brno
country: Czechia
city: Bruntal
country: Czechia
city: Hlucin
country: Czechia
city: Ostrava-Trebovice
country: Czechia
city: Prague
country: Czechia
city: Uherske Hradiste
country: Czechia
city: Zlin
country: Czechia
city: Berlin
country: Germany
city: Frankfurt
country: Germany
city: Hannover
country: Germany
city: Herne
country: Germany
city: Leipzig
country: Germany
city: Mainz
country: Germany
city: Wurzburg
country: Germany
city: Balatonfured
country: Hungary
city: Bekescsaba
country: Hungary
city: Budapest
country: Hungary
city: Szekesfehervar
country: Hungary
city: Veszprem
country: Hungary
city: Amsterdam
country: Netherlands
city: Chelm Slaski
country: Poland
city: Elblag
country: Poland
city: Grodzisk Mazowiecki
country: Poland
city: Krakow
country: Poland
city: Lublin
country: Poland
city: Poznan
country: Poland
city: Warsaw
country: Poland
city: Zyrardow
country: Poland
city: Bacau
country: Romania
city: Baia Mare
country: Romania
city: Braila
country: Romania
city: Bucharest
country: Romania
city: Galati
country: Romania
city: Saint Gheorghe, Covasna
country: Romania
city: Targoviste
country: Romania
city: Donetsk
country: Ukraine
city: Kharkov
country: Ukraine
city: Kiev
country: Ukraine
Study officials:
affiliation: Amgen
name: MD
role: STUDY_DIRECTOR
References: